Cerebroprotein hydrolysate in traumatic brain injury

Karia, Sagar; Mahajan, Priyanka Thukral; Shah, Nilesh; Sonavane, Sushma; Sousa, Avinash De

doi:10.18035/emj.v2i1.55

Cited by 4 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary brain injury is the leading cause of hospital deaths after TBI. [6] Cerebroprotein hydrolysate (CH) is a unique neurotrophic peptidergic mixture produced by standardised enzymatic breakdown of lipid-free porcine brain proteins. [7] It has unique neurotrophic activity that enhances neurogenesis, neuronal survival, provides neuromodulatory action, increases neuronal plasticity and neuronal repair and has neuro-immunotrophic actions.…”

Section: Discussionmentioning

confidence: 99%

Role of Cerebroprotein Hydrolysate in Outcome and Recovery of Traumatic Brain Injury

Chaurasia¹,

Parihar²,

Gehlot³

et al. 2018

jemds

View full text Add to dashboard Cite

BACKGROUNDTraumatic Brain Injury (TBI) is a complex injury with a wide range of symptoms and disabilities, which can lead to a lifelong devastating effect on the patient and the family. Its (TBI) incident is increasing day-by-day. There is a need of better management in traumatic brain injury patient to reduce the mortality and associated with it. Cerebroprotein hydrolysate is a recent neurotrophic and neuroprotective drug which is in use for acute ischaemic strokes, vascular dementia, Alzheimer's disease and traumatic brain injuries with its proven potential. Aims and Objectives-Our work aims to evaluate the effectiveness and safety of cerebroprotein hydrolysate in the management of brain injury patients. MATERIALS AND METHODSA randomised controlled trial used in the study and the sample size was taken for convenience during the study. This study was conducted on 200 patients and the patients were randomly divided into two groups. Group 1 (study group, n= 100) received cerebroprotein hydrolysate for 14 -21 days and Group 2 (control group, n= 100) received only conventional therapy. Both the groups were assessed with GCS (Glasgow Coma Score), APACHE Π (Acute Physiology and Chronic Health Evaluation II) scores and CT/ MRI Brain on admission and were compared in terms of degree of improvement on 14 -21 days from the day of admission. RESULTSPatient on cerebroprotein hydrolysate was compared to conventional therapy (control) group. Patients with cerebroprotein hydrolysate showed statistical significance (p value= 0.001) in regard to GCS and in terms of functional and cognitive outcome. CONCLUSIONOur study concludes that the usage of cerebroprotein hydrolysate therapy can be safe and useful in traumatic brain injury in terms of functional and cognitive outcome with better recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Cerebroprotein Hydrolysate in Outcome and Recovery of Traumatic Brain Injury

Chaurasia¹,

Parihar²,

Gehlot³

et al. 2018

jemds

View full text Add to dashboard Cite

show abstract

“…Cerebroprotein hydrolysate has been found to be useful in Traumatic brain injury, acute ischaemic stroke, Vascular dementia, Extrapontine myelinolysis and Alzheimer's disease (AD) [10][11][12].…”

Section: Cerebroproteinmentioning

confidence: 99%

Cerebroprotein Hydrolysate- New Paradigm in Management of Neurological Problems

Oommen¹

2015

JNSK

View full text Add to dashboard Cite

“…It has been reported that cerebroprotein via certain mechanism enhances neurogenesis, neuronal survival and neuronal plasticity and also has neuro immunotropic mechanism of action [1]. By improving the metabolism of neuron and protecting nerve damage studies have shown cerebroprotein hydrolysate to be useful in vascular dementia, Alzheimer's disease, traumatic brain injury, acute ischaemic stroke and extrapontine myelin lysis [2][3][4]. Cerebroprotein hydrolysate augmented proliferation, differentiation and migration of adult subventricular zone (SVZ) neural progenitor cells resulting in increased number of neural progenitor cells and neuroblasts to contribute to neurogenesis.…”

Section: Introductionmentioning

confidence: 99%

Cerebroprotein Hydrolysate Induced Systemic Inflammatory Response Syndrome (Sirs): A Case Report

Devi

Sarma²,

Choudhury

2016

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Cerebroprotein hydrolysate is a newer pharmacological neurotropic agent and considered as a promising therapeutic agent for dementia, Alzheimer's disease, traumatic brain injury and acute ischaemic stroke. Studies revealed that most of the side effects are minor. Here, we reported a case of Systemic inflammatory response syndrome (SIRS) probably due to use of Cerebroprotein hydrolysate in a patient with acute ischaemic stroke.

show abstract

Cerebroprotein hydrolysate in traumatic brain injury

Cited by 4 publications

References 7 publications

Role of Cerebroprotein Hydrolysate in Outcome and Recovery of Traumatic Brain Injury

Role of Cerebroprotein Hydrolysate in Outcome and Recovery of Traumatic Brain Injury

Cerebroprotein Hydrolysate- New Paradigm in Management of Neurological Problems

Cerebroprotein Hydrolysate Induced Systemic Inflammatory Response Syndrome (Sirs): A Case Report

Contact Info

Product

Resources

About